This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488.
Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65: 2628–2640.
Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M et al. Rising pp65antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867–874.
Ottinger HD, Beelen DW, Schaefer UW, Grosse-Wilde H . Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.
Trenschel R, Bernier M, Delforge A, Massy M, Lebeau De Hemricourt E, Maerevoet M et al. Myeloid and lymphoid recovery following bone marrow transplantation: a comparative study between related, unrelated bone marrow and allogeneic stem cell transplantation. Leuk lymphoma 1998; 30: 325–352.
Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665–672.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant 1995; 15: 825.
Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880.
Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360–4367.
Boeckh M, Ljungman P . How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711–5719.
Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette-Bodin C, Coste-Burel M et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010; 45: 1204–1211.
Acknowledgements
This work was funded by Jiangsu Provincial Special Program of Medical Science (BL2012005); Jiangsu Province’s Key Medical Center (ZX201102) and the Priority Academic; Program Development of the Jiangsu Higher Education Institutions (PAPD); National clinical key subject project; National Natural Science Foundation of China (Grant No.81370626).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Bao, X., Zhu, Q., Xue, S. et al. Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China. Bone Marrow Transplant 51, 1625–1627 (2016). https://doi.org/10.1038/bmt.2016.231
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.231
This article is cited by
-
Biofilm formation of pathogenic bacteria isolated from aquatic animals
Archives of Microbiology (2023)